Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker

NCT ID: NCT03830957

Last Updated: 2019-04-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-26

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to compare the effects of Ivabradine and metoprolol to reduce heart rate prior to coronary CT angiography in patients with advanced heart failure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure CT Angiography Ischemic Cardiomyopathy Non-ischemic Cardiomyopathy Heart Failure, Systolic Heart Failure,Congestive Heart Failure, Diastolic Heart Rate Low

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ivabradine

Group Type ACTIVE_COMPARATOR

Ivabradine

Intervention Type DRUG

7.5 mg oral single dose if the heart rate would not reach to 60/minute then give another dose, 7.5 mg

metoprolol

Group Type ACTIVE_COMPARATOR

Metoprolol

Intervention Type DRUG

5 mg oral single dose if the heart rate would not reach to 60/minute then give another dose, 5 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ivabradine

7.5 mg oral single dose if the heart rate would not reach to 60/minute then give another dose, 7.5 mg

Intervention Type DRUG

Metoprolol

5 mg oral single dose if the heart rate would not reach to 60/minute then give another dose, 5 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Sinus rhythm
* Heart rate \>60/min

Exclusion Criteria

* Atrial fibrillation
* Any contraindication for beta-blocker use
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rajaie Cardiovascular Medical and Research Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ahmad Amin

Tehran, , Iran

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Iran

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ahmad Amin, MD

Role: primary

+98 21 2392 ext. 2172

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HFRC_01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Nitrite and Coronary Flow Study
NCT04354051 COMPLETED PHASE1/PHASE2